SREBF2 and melanoma: Targeted genetic silencing of SREBP2 in DCs, as well as its pharmacologic inhibition, enhanced antitumor CD8 + T cell activation and inhibited melanoma progression.280 Moreover, Caronni revealed that lactate inhibited DCs from presenting antigens and activating CD8 + T cells when co-cultured with Lewis lung carcinoma (LLC) cells, thus preventing them from initiating an immune response within LLC models in vivo.281 Furthermore, Nasi et al. uncovered that the lactate-induced changes in DCs might be density-dependent.